Bristol-Myers Squibb Co. has settled a securities class action suit for a $125 million. The Plaintiffs accused the drug maker of misleading shareholders and causing a stock drop when it failed to properly disclose a patent deal for a generic version of its blood-thinning drug Plavix. The settlement, reached in May, was disclosed to the public in the company’s quarterly report filed with the U.S. Securities and Exchange Commission.
Source: Law 360
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.